AMGN - Amgen Inc.
After hours:
Chart Events
Relative Strength Index (RSI)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 217.46 |
| Open | 215.96 |
| Bid | 217.00 x 1000 |
| Ask | 217.20 x 1200 |
| Day's Range | 214.48 - 218.44 |
| 52 Week Range | 214.48 - 296.67 |
| Volume | |
| Avg. Volume | 2,270,730 |
| Market Cap | 115.912B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | 14.75 |
| EPS (TTM) | 14.71 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | 8.52 (3.93%) |
| Ex-Dividend Date | May 17, 2023 |
| 1y Target Est | 254.55 |
Fair Value
Related Research
PR NewswireAMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT
Amgen (NASDAQ: AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on Wednesday, May 31, 2023. David M. Reese, M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
ZacksIs the Options Market Predicting a Spike in Amgen (AMGN) Stock?
Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.
Motley FoolA Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know.
When you think of Johnson & Johnson (NYSE: JNJ), you may think of shampoo and Band-Aids. In fact, J&J is in the process of spinning off that business into an entity called Kenvue. What is J&J's top revenue driver?
Insider Monkey14 Best Biotech Stocks To Buy According To Hedge Funds
In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […]
Insider Monkey14 Best Healthcare Dividend Stocks to Buy
In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and […]
The Wall Street JournalElizabeth Warren and the FTC Are the Least of Amgen’s Problems
The Internal Revenue Service has gone after the biotech for billions of dollars in back taxes. Lina Khan’s Federal Trade Commission is seeking to block its $27.8 billion acquisition of Horizon Therapeutics (a move some insiders think was at least partly prompted by a blistering letter from Sen. Elizabeth Warren).
Motley FoolFTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
The Federal Trade Commission (FTC) has been taking a much more adversarial approach to mergers and acquisitions lately. For instance, it recently said it plans to block the pending deal between pharmaceutical companies Horizon Therapeutics (NASDAQ: HZNP) and Amgen (NASDAQ: AMGN). Does the FTC's recent tough stance on big deals increase the chances that Pfizer's (NYSE: PFE) acquisition of Seagen (NASDAQ: SGEN) will also run into problems?
- Reuters
UPDATE 1-US judge hearing fight over Amgen deal for Horizon eyes September trial
The judge who will decide if Amgen can go forward with its $27.8 billion purchase of Horizon Therapeutics on Tuesday said he was considering an evidentiary hearing on the matter in September. Judge John Kness said he would likely take about four weeks after the hearing ends to make a ruling. The case is being heard in federal court in Chicago.
- Reuters
UPDATE 2-Amgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
Johnson & Johnson has settled its lawsuit over Amgen Inc's proposed biosimilar version of J&J's top-selling treatment Stelara for psoriasis and other autoimmune conditions, according to a filing in Delaware federal court. Amgen said in a statement on Tuesday that the settlement terms are confidential, but it will allow the company to sell its biosimilar of Stelara "no later than January 1st, 2025."
ReutersAmgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
(Reuters) -Johnson & Johnson has settled its lawsuit over Amgen Inc's proposed biosimilar version of J&J's top-selling treatment Stelara for psoriasis and other autoimmune conditions, according to a filing in Delaware federal court. Amgen said in a statement on Tuesday that the settlement terms are confidential, but it will allow the company to sell its biosimilar of Stelara "no later than January 1st, 2025." A J&J spokesperson said the company will "continue to defend the intellectual property associated with our medicines to protect our ability to innovate and develop life-changing therapies for patients."
- Investing.com
4 big deal reports: Amgen-Horizon merger on the ropes
Here is your Pro Recap of 4 head-turning deal dispatches you may have missed this week: potential block of Horizon/Amgen transaction, merger deals at Magellan Midstream/Oneok and Urstadt Biddle/Regency Centers, and New Relic’s potential $5B acquisition. InvestingPro subscribers got this news before anyone else. Horizon Therapeutics (NASDAQ:HZNP) shares plunged more than 14% on Tuesday after the report that the U.S. Federal Trade Commission (FTC) is expected to introduce a lawsuit to block the proposed $27.8 billion merger with Amgen (NASDAQ:AMGN).
Simply Wall St.We Think Amgen (NASDAQ:AMGN) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
The Wall Street JournalWalmart, Tesla, Micron: Stocks That Defined the Week
Retail giant Walmart posted stronger-than-expected profit and revenue and raised its full-year profit outlook, as the company’s stores attract price-sensitive customers who have curtailed spending elsewhere. Walmart said it continued to gain grocery market share, including among higher-income shoppers. Walmart shares rose 1.3% Thursday.
Barrons.comWashington Is Coming Down Hard on Deal Making. What It Means for Stocks.
FTC Chair Khan now seems less interested in ensuring competition than in blocking all linkups on principle.
- Financial Times
A global antitrust alliance battles Microsoft and Amgen
As the EU approved Microsoft’s $75bn bid to buy Activision Blizzard, the US Federal Trade Commission sued to block Amgen’s $28.3bn deal to acquire Horizon Therapeutics and warned of “rampant consolidation” in pharmaceuticals. Margrethe Vestager, EU competition commissioner, is known as the nemesis of Big Tech but others are taking her place. The Amgen suit epitomises the tough approach adopted by Lina Khan, chair of the FTC, and Khan has a new ally: Sarah Cardell, chief executive of the UK Competition and Markets Authority.
Investopedia5 Things to Know Before Markets Open
President Biden said he was confident that negotiators would reach a deal on the debt ceiling and Fed Chair Jerome Powell is set to speak on monetary policy. Here’s what investors need to know today.
Motley Fool3 Safe Dividend Stocks to Beat Inflation
Inflation rates may finally be cooling down from last year's unnerving levels. Plenty of dividend-paying companies are dishing out -- and growing -- their dividend payments generously enough to outpace inflation's impact. Here's a closer look at three such dividend stocks to consider adding to the income-paying portion of your portfolio.
Motley FoolWhy Viking Therapeutics Stock Is Buckling Today
Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics (NASDAQ: VKTX) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. Small- and mid-cap biotech stocks are under pressure today following the Federal Trade Commission's (FTC) decision to sue over the proposed merger between Amgen and Horizon Therapeutics earlier this week. Before investors get too concerned, however, it's important to understand what's actually driving this takeover speculation.
The Wall Street JournalSanofi Wins Supreme Court Patent Dispute With Amgen
The court said Amgen patents relating to its cholesterol drug Repatha shouldn’t have been granted by the patent office, handing a victory to rival pharmaceutical firm Sanofi.
- Reuters
UPDATE 3-U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents
The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha in a legal clash with French rival Sanofi SA. The 9-0 ruling upheld a lower court's decision that had invalidated Amgen's patents on the grounds that the Thousand Oaks, California-based drugmaker had failed to provide a roadmap for recreating, or "enabling," the full scope of its claimed innovation. Conservative Justice Neil Gorsuch wrote for the court that "we agree with the lower courts that Amgen has failed to enable all that it has claimed, even allowing for a reasonable degree of experimentation."
ReutersU.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents
WASHINGTON (Reuters) -The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha in a legal clash with French rival Sanofi SA. The 9-0 ruling upheld a lower court's decision that had invalidated Amgen's patents on the grounds that the Thousand Oaks, California-based drugmaker had failed to provide a roadmap for recreating, or "enabling," the full scope of its claimed innovation. Conservative Justice Neil Gorsuch wrote for the court that "we agree with the lower courts that Amgen has failed to enable all that it has claimed, even allowing for a reasonable degree of experimentation."
- Reuters
UPDATE 1-Amgen agrees not to seek quick close to Horizon acquisition
Amgen Inc has agreed not to quickly close on its $27.8 billion acquisition of Horizon Therapeutics after the U.S. Federal Trade Commission (FTC) filed suit to block the deal. A U.S. district court judge issued a temporary restraining order late on Wednesday after the two companies and the FTC reached an agreement that both sides said in a joint filing would permit a full briefing and "less-compressed consideration" by the court of the FTC request. Absent an agreement, Amgen could have sought to close the deal as early as Monday.
ReutersAmgen agrees not to seek quick close to Horizon acquisition
Amgen Inc has agreed not to quickly close on its $27.8 billion acquisition of Horizon Therapeutics after the U.S. Federal Trade Commission (FTC) filed suit to block the deal. A U.S. district court judge issued a temporary restraining order late on Wednesday after the two companies and the FTC reached an agreement that both sides said in a joint filing would permit a full briefing and "less-compressed consideration" by the court of the FTC request. Absent an agreement, Amgen could have sought to close the deal as early as Monday.
- Reuters
U.S. court issues temporary restraining order on $27.8 bln Amgen-Horizon deal
A U.S. district court has issued a temporary restraining order on Amgen Inc's $27.8 billion acquisition of Horizon Therapeutics following a submission for it by the two companies and the U.S. Federal Trade Commission, Amgen said on Wednesday. Under the order, Amgen and Horizon would not close their transaction until the earlier of Sept. 15 or the second business day after the court rules on the FTC's lawsuit filed on Tuesday.
ReutersFTC effort to stop Amgen's Horizon takeover faces uphill fight
The Federal Trade Commission (FTC) faces an uphill battle in its fight against Amgen Inc's $27.8 billion acquisition of Horizon Therapeutics with an untested argument before a Trump-appointed judge, three antitrust experts said. Furthermore, the FTC's complaint, unsealed late Tuesday, expresses concern about deals struck between drug companies that give discounts to pharmacy benefit managers and insurers in return for making their medicines easier to get for their customers. "Any time a complaint is putting forth a novel theory it's an uphill battle," said Katie Funk, an antitrust attorney at Baker, Donelson, adding that they will need to convince the judge that "the alleged anticompetitive effects are not baseless, but are serious and substantial."